Related Experiment Video

Updated: May 16, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Efficacy of DPP-4 inhibitor evaluated by CGM (continuous glucose monitoring)]

Rimei Nishimura1

  • 1Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 11, 2012
PubMed

Insights

DPP-4 inhibitors improve blood sugar control in diabetes patients by enhancing incretin action, promoting glucose-dependent insulin release, and preventing hypoglycemia. Continuous glucose monitoring (CGM) effectively evaluated their efficacy.

Area of Science:

  • Endocrinology
  • Pharmacology

Context:

  • Diabetes mellitus management aims to prevent complications and cardiovascular events.
  • Optimal glycemic control and avoidance of hypoglycemia are crucial for patients.
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors offer a therapeutic strategy by modulating the incretin system.

Purpose:

  • To evaluate the efficacy of DPP-4 inhibitors in managing hyperglycemia in diabetic patients.
  • To assess the impact of DPP-4 inhibition on glucose fluctuations and hypoglycemia risk.

Summary:

  • DPP-4 inhibitors enhance endogenous incretin effects, leading to glucose-dependent insulin secretion and regulated glucagon secretion.
  • This mechanism improves postprandial hyperglycemia without inducing hypoglycemia.
  • Continuous glucose monitoring (CGM) was employed to continuously track blood glucose fluctuations and assess treatment effectiveness.

Impact:

  • DPP-4 inhibitors represent a valuable therapeutic option for improving glycemic control in diabetes.
  • The use of CGM provides objective data on the efficacy and safety profile of these agents.
  • Understanding the role of DPP-4 inhibition contributes to personalized diabetes management strategies.

More Related Videos

Simple Continuous Glucose Monitoring in Freely Moving Mice03:25

Simple Continuous Glucose Monitoring in Freely Moving Mice

Published on: February 24, 2023

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...